Balancing Near Term ROI and Foundational AI Innovation

Al‑Quraishi distinguishes between AI tools that deliver immediate commercial value, such as OpenFold‑style models and Boltz, and deeper scientific problems that require long‑term investment before their impact is felt. While industry naturally focuses on near‑term returns, he argues that foundational work—often overlooked by pharma—can unlock transformative capabilities years later. Sustained support is needed to push these early‑stage ideas far enough to ultimately create real value for drug discovery.